{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T05:05:28Z","timestamp":1780031128359,"version":"3.53.1"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiovascular risk in type 1 diabetes mellitus (T1DM) is frequently underestimated in daily clinical practice. The aim was therefore to evaluate lipid management in patients with T1DM according to current guidelines, and agreement in target attainment across three recommended lipid biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Target attainment of (low-density lipoprotein cholesterol [LDL-C, estimated with the Friedewald formula], non-high-density lipoprotein cholesterol [non-HDL-C], and apolipoprotein B [apoB]) was determined based on the 2021 European Society of Cardiology Dyslipidemia guideline among adult patients with T1DM enrolled in SwissDiab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median age of the 216 patients included was 43.6 years, diabetes duration 16 years, HbA1c 7.3% (56 mmol\/mol), 39.4% were females, 75.0% were at high, and 11.6% at very high cardiovascular risk. Prescription of lipid-lowering therapy (LLT) was low (33.6%). LDL-C target attainment was poor (11.6%), while significantly more patients reached non-HDL-C (30.6%) and apoB (59.7%) targets (P-values &amp;lt;0.00001). Overall, 11.1% of the patients reached all three, and 39.8% none of the lipid targets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Raised awareness of the importance of lipid management in T1DM is needed. However, the observed discordance in target attainment across lipid biomarkers can lead to uncertainties in clinical decision-making on how to best apply current lipid management recommendations for optimal cardiovascular risk prevention in T1DM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1819019","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:48:35Z","timestamp":1780030115000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Patients with type 1 diabetes mellitus and recommended low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and apolipoprotein B targets \u2013 a SwissDiab study"],"prefix":"10.3389","volume":"17","author":[{"given":"Christina","family":"Liu","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Diabetes, Cantonal Hospital St.Gallen, HOCH Health Ostschweiz","place":["St. Gallen, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frida","family":"Renstr\u00f6m","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes, Cantonal Hospital St.Gallen, HOCH Health Ostschweiz","place":["St. Gallen, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Gastaldi","sequence":"additional","affiliation":[{"name":"DiaCentre \u2013 Maison Du Diab\u00e8te, Hirslanden Hill Clinic","place":["Ch\u00eane-Bougeries, Switzerland"]},{"name":"Department of Medical Specializations, Diabetology, Geneva University Hospitals","place":["Geneva, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Br\u00e4ndle","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes, Cantonal Hospital St.Gallen, HOCH Health Ostschweiz","place":["St. Gallen, Switzerland"]},{"name":"Division of General Internal, Family, and Emergency Medicine, Cantonal Hospital St. Gallen, HOCH Health Ostschweiz","place":["St. Gallen, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Bilz","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes, Cantonal Hospital St.Gallen, HOCH Health Ostschweiz","place":["St. Gallen, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081798","article-title":"Cardiovascular disease in type 1 diabetes mellitus: Epidemiology and management of cardiovascular risk","volume":"10","author":"Colom","year":"2021","journal-title":"J Clin Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408214","article-title":"Glycemic control and excess mortality in type 1 diabetes","volume":"371","author":"Lind","year":"2014","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-2249","article-title":"A patient-level model to estimate lifetime health outcomes of patients with type 1 diabetes","volume":"43","author":"Tran-Duy","year":"2020","journal-title":"Diabetes Care"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-0612-8","article-title":"Cardiovascular risk in type 1 diabetes mellitus","volume":"10","author":"Schofield","year":"2019","journal-title":"Diabetes Ther Res Treat Educ Diabetes Relat Disord"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2311526","article-title":"Prevention of cardiovascular disease in type 1 diabetes","volume":"390","author":"Manrique-Acevedo","year":"2024","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.06.050","article-title":"Progression of coronary artery calcium in type 1 diabetes mellitus","volume":"100","author":"Costacou","year":"2007","journal-title":"Am J Cardiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2839","article-title":"Cardiovascular and renal disease burden in type 1 compared with type 2 diabetes: A two-country nationwide observational study","volume":"44","author":"Krist\u00f3fi","year":"2021","journal-title":"Diabetes Care"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1990","article-title":"Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: The DCCT\/EDIC study 30-year follow-up","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non\u2013HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: A meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.07.045","article-title":"Beyond low-density lipoprotein cholesterol","volume":"50","author":"Mudd","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11100690","article-title":"Apolipoprotein B and cardiovascular disease: Biomarker and potential therapeutic target","volume":"11","author":"Behbodikhah","year":"2021","journal-title":"Metabolites"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: New models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad260","article-title":"SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe","volume":"44","year":"2023","journal-title":"Eur Heart J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.5080","article-title":"Apolipoprotein B vs low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as the primary measure of apolipoprotein B lipoprotein-related risk: The debate is over","volume":"7","author":"Sniderman","year":"2022","journal-title":"JAMA Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S2213-8587(19)30388-2","article-title":"Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: A systematic review and meta-analysis of randomised trials including 327\u2008037 participants","volume":"8","author":"Wang","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-024-01039-5","article-title":"The LDL cumulative exposure hypothesis: Evidence and practical applications","volume":"21","author":"Ference","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"996","DOI":"10.2337\/dc15-2450","article-title":"Association between use of lipid-lowering therapy and cardiovascular diseases and death in individuals with type 1 diabetes","volume":"39","author":"Hero","year":"2016","journal-title":"Diabetes Care"},{"key":"B19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae258","article-title":"Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: Implications for cardiovascular prevention","volume":"45","author":"Sniderman","year":"2024","journal-title":"Eur Heart J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.131150","article-title":"Concordance\/discordance between serum apolipoprotein B, low density lipoprotein cholesterol and non-high density lipoprotein cholesterol in NATPOL 2011 participants - An epidemiological perspective","volume":"390","author":"Solnica","year":"2023","journal-title":"Int J Cardiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2012.08.039","article-title":"Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study","volume":"225","author":"Sniderman","year":"2012","journal-title":"Atherosclerosis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16335","article-title":"Discordance between serum cholesterol concentration and atherogenic lipoprotein particle number in people with metabolic disease: A systematic review","volume":"27","author":"Witt","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15264","article-title":"Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German-Austrian diabetes registry","volume":"25","author":"Brandts","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2009.05.013","article-title":"Apolipoprotein B levels in adults with type 1 diabetes not receiving lipid-lowering therapy","volume":"42","author":"Mazanderani","year":"2009","journal-title":"Clin Biochem"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.07.020","article-title":"Relation of combined non\u2013high-density lipoprotein cholesterol and apolipoprotein B with atherosclerosis in adults with type 1 diabetes mellitus","volume":"116","author":"Bjornstad","year":"2015","journal-title":"Am J Cardiol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/clc.24334","article-title":"Safety and effectiveness of high\u2010intensity statins versus low\/moderate\u2010intensity statins plus ezetimibe in patients with atherosclerotic cardiovascular disease for reaching LDL\u2010C goals: A systematic review and meta\u2010analysis","volume":"47","author":"Soleimani","year":"2024","journal-title":"Clin Cardiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"B32","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1001\/jamacardio.2020.0013","article-title":"A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and\/or hypertriglyceridemia","volume":"5","author":"Sampson","year":"2020","journal-title":"JAMA Cardiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12944-020-01292-w","article-title":"Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol","volume":"19","author":"Fonseca","year":"2020","journal-title":"Lipids Health Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2010.03.005","article-title":"Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol","volume":"4","author":"Sniderman","year":"2010","journal-title":"J Clin Lipidol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1515\/cclm-2019-1253","article-title":"Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM","volume":"58","author":"Langlois","year":"2020","journal-title":"Clin Chem Lab Med CCLM"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2020.09.001","article-title":"Cardiovascular disease in type 1 diabetes: A review of epidemiological data and underlying mechanisms","volume":"46","author":"Verg\u00e8s","year":"2020","journal-title":"Diabetes Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13528","article-title":"Management of LDL\u2010cholesterol levels in patients with diabetes mellitus in cardiology practice: Real\u2010life evidence of under\u2010treatment from the EPHESUS registry","volume":"51","author":"Mert","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2022-002765","article-title":"Cardiovascular risk management in people with type 1 diabetes: Performance using three guidelines","volume":"10","author":"Varkevisser","year":"2022","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.endinu.2019.02.004","article-title":"Prevalence and factors associated with statin use in high-risk patients with type 1 diabetes from a specialized diabetes unit","volume":"66","author":"Amor","year":"2019","journal-title":"Endocrinol Diabetes Nutr"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2025-112682","article-title":"Statin prescription rates for prevention of atherosclerotic cardiovascular disease in adults 40\u201375 years old with type 1 diabetes","volume":"16","author":"Lundholm","year":"2026","journal-title":"BMJ Open"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.98557","article-title":"Eligible but untreated: Gaps in statin therapy for type 1 diabetes under the National Institute for Health and Care Excellence (NICE) guidelines","volume":"17","author":"Riasat","year":"2025","journal-title":"Cureus"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100546","article-title":"Age-based disparities in guideline-recommended statin initiation for primary prevention among statin-naive adults","volume":"2","author":"Zheutlin","year":"2023","journal-title":"JACC Adv"},{"key":"B43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12933-015-0318-9","article-title":"Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: Results from the Canadian study of longevity in diabetes cohort","volume":"15","author":"Bai","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-023-01866-x","article-title":"Hyperlipidemia and cardiovascular disease in people with type 1 diabetes: Review of current guidelines and evidence","volume":"25","author":"Karmali","year":"2023","journal-title":"Curr Cardiol Rep"},{"key":"B45","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S2213-8587(14)70248-7","article-title":"Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: A systematic review and meta-analysis","volume":"3","author":"Huxley","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-12-78","article-title":"Sex-specific-differences in cardiometabolic risk in type 1 diabetes: A cross-sectional study","volume":"12","author":"Kautzky-Willer","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1186\/1758-5996-6-117","article-title":"Sex-based disparities in cardioprotective medication use in adults with diabetes","volume":"6","author":"Butalia","year":"2014","journal-title":"Diabetol Metab Syndr"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2018.04.068","article-title":"Non-achievement of LDL-cholesterol targets in patients with diabetes at very-high cardiovascular risk receiving statin treatment: Incidence and risk factors","volume":"268","author":"Breuker","year":"2018","journal-title":"Int J Cardiol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.30710","article-title":"Cardiometabolic risk factors and incident cardiovascular disease events in women vs men with type 1 diabetes","volume":"5","author":"Braffett","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B50","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1186\/s12916-024-03698-0","article-title":"Sex disparities in the prevalence, incidence, and management of diabetes mellitus: An Australian retrospective primary healthcare study involving 668,891 individuals","volume":"22","author":"Mnatzaganian","year":"2024","journal-title":"BMC Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s12933-024-02419-4","article-title":"Sex inequalities in cardiovascular risk factors and their management in primary prevention in adults living with type 1 diabetes in Germany and France: findings from DPV and SFDT1","volume":"23","author":"Cosson","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.atherosclerosis.2021.05.006","article-title":"Fetal toxicity associated with statins: a systematic review and meta-analysis","volume":"327","author":"Vahedian-Azimi","year":"2021","journal-title":"Atherosclerosis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13101087","article-title":"Gender-related factors in medication adherence for metabolic and cardiovascular health","volume":"13","author":"Venditti","year":"2023","journal-title":"Metabolites"},{"key":"B54","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13293-024-00642-y","article-title":"Sex specific analysis of patients with and without reported statin intolerance referred to a specialized outpatient lipid clinic","volume":"15","author":"Muck","year":"2024","journal-title":"Biol Sex Diff"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2023.117269","article-title":"Sex-specific differences in cardiovascular risk factors and implications for cardiovascular disease prevention in women","volume":"384","author":"Rajendran","year":"2023","journal-title":"Atherosclerosis"},{"key":"B56","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s12471-010-0841-y","article-title":"Gender differences in coronary heart disease","volume":"18","author":"Maas","year":"2010","journal-title":"Neth Heart J Mon J Neth Soc Cardiol Neth Heart Found"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-015-0554-0","article-title":"Excess cardiovascular risk in diabetic women: a case for intensive treatment","volume":"17","author":"Recarti","year":"2015","journal-title":"Curr Hypertens Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31506-X","article-title":"Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study","volume":"392","author":"Rawshani","year":"2018","journal-title":"Lancet"},{"key":"B59","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12933-025-02791-9","article-title":"Cardiovascular disease in women with type 1 diabetes: a narrative review and insights from a population-based cohort analysis","volume":"24","author":"Mesa","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/clinchem\/hvad190","article-title":"The Sampson-NIH equation is the preferred calculation method for LDL-C","author":"Sampson","year":"2024","journal-title":"Clin Chem"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2021.20525","article-title":"Representativeness of the Swiss Diabetes Registry \u2013 a single centre analysis","volume":"151","author":"Eichm\u00fcller","year":"2021","journal-title":"Swiss Med Wkly"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa034","article-title":"Application of the 2019 ESC\/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study","volume":"41","author":"Allahyari","year":"2020","journal-title":"Eur Heart J"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwad178","article-title":"An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology\/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study","volume":"30","author":"Singeisen","year":"2023","journal-title":"Eur J Prev Cardiol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1819019\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:48:38Z","timestamp":1780030118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1819019\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":63,"alternative-id":["10.3389\/fendo.2026.1819019"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1819019","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1819019"}}